In this clinical context, MYC/MYCN amplification and LCA were not associated with each other, with clinical high-risk factors (one MYCN/R+ and one MYCN/LCA tumor were observed) or with poor prognosis when observed in isolation as risk-factors in the clinically-defined non-metastatic/standard-risk group reported. This evidence concerns the gene MYC and neoplasm.